Program
Cyclosporine
Also written as “cyclosporine”, “Cyclosporine A” and “Ciclosporin”.
Its studies are mostly in Dry Eye Syndromes · Dermatitis, Atopic · Bronchiolitis Obliterans Syndrome · Conjunctivitis, Allergic · Bronchiolitis Obliterans, led by 26 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 220 open or running | phase 4since Sep 6, 2005 | Sep 6, 2005 | none ahead |
| Pfizer | 80 open or running | phase 4since Sep 13, 2005 | Jun 30, 2004 | none ahead |
| Hoffmann-La Roche | 70 open or running | phase 4since Jun 30, 2005 | Jun 30, 2005 | none ahead |
| Santen Pharmaceutical | 50 open or running | phase 3since May 19, 2006 | May 19, 2006 | none ahead |
| AbbVie | 40 open or running | phase 4since Apr 22, 2014 | Apr 17, 2009 | none ahead |
| Zambon SpA | 40 open or running | phase 3since Aug 30, 2018 | Aug 30, 2018 | none ahead |
| Sirion Therapeutics | 30 open or running | phase 3since Jul 13, 2007 | Jul 13, 2007 | none ahead |
| amsterdam-molecular-therapeutics | 20 open or running | phase 3since Apr 30, 2009 | Apr 30, 2009 | none ahead |
| apt-pharmaceuticals-inc | 20 open or running | phase 3since Sep 17, 2008 | Sep 17, 2008 | none ahead |
| Hanlim Pharm. | 20 open or running | phase 3since Dec 10, 2012 | Dec 10, 2012 | none ahead |
| Innovative Medical | 20 open or running | phase 4since Jul 5, 2006 | Jul 5, 2006 | none ahead |
| Novaliq | 20 open or running | phase 4since Mar 19, 2024 | Nov 25, 2015 | none ahead |
| perle-bioscience-inc | 20 open or running | phase 3since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| Research Insight | 20 open or running | phase 4since Apr 6, 2020 | Apr 6, 2020 | none ahead |
| sigmoid-pharma | 20 open or running | phase 2since Dec 15, 2009 | Dec 15, 2009 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | phase 4since Apr 8, 2020 | Feb 13, 2016 | none ahead |
| fovea-pharmaceuticals-sa | 10 open or running | phase 2since Apr 29, 2010 | Apr 29, 2010 | none ahead |
| isdin | 10 open or running | phase 2since Dec 20, 2007 | Dec 20, 2007 | none ahead |
| LEO Pharma | 10 open or running | phase 4since Oct 16, 2018 | Oct 16, 2018 | none ahead |
| pari-pharma-gmbh | 10 open or running | phase 3since Apr 11, 2011 | Apr 11, 2011 | none ahead |
| perioc-limited | 10 open or running | phase 2since Feb 12, 2015 | Feb 12, 2015 | none ahead |
| Pharming Group | 10 open or running | phase 1since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| spherium-biomed | 10 open or running | phase 2since Aug 4, 2016 | Aug 4, 2016 | none ahead |
| sublimity-therapeutics-holdco-limited | 10 open or running | phase 2since Jan 31, 2019 | Jan 31, 2019 | none ahead |
| Takeda | 10 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd | 11 open or running | phase 3since Jan 3, 2025 | Jan 3, 2025 | none ahead |
Also a collaborator on its studies: parexel, Dr. Falk Pharma, syreon-corporation and the-clinical-trial-company.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jan 8, 2007.
- Nov 4, 2016Phase 2 study in Anemia, AplasticNovartis · NCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
- Aug 30, 2018Zambon SpA's first studies: 2 phase 3 studies in Bronchiolitis ObliteransNew to Zambon SpAZambon SpA · NCT03657342, NCT03656926
- Oct 16, 2018LEO Pharma's first study: phase 4 study in Dermatitis, AtopicNew to LEO PharmaLEO Pharma · NCT03710044 · Netherlands
- Jan 31, 2019sublimity-therapeutics-holdco-limited's first study: phase 2 study in Colitis, UlcerativeNew to sublimity-therapeutics-holdco-limitedsublimity-therapeutics-holdco-limited · NCT03844932 · 235 enrolled · United States, Belarus, Bulgaria and more
- Jul 19, 2019Phase 3 study in Bronchiolitis ObliteransZambon SpA · NCT04039347 · 164 enrolled · United States, Austria, Belgium and more
- Sep 25, 2019Phase 2 study in Bronchiolitis Obliterans SyndromeZambon SpA · NCT04107675 · 6 enrolled · France, Germany, Spain
- Oct 25, 2019Phase 3 study in Dry Eye Disease With Severe KeratitisSanten Pharmaceutical · NCT04144413 · 350 enrolled · Czechia, France, Italy and more
- Mar 9, 2020Phase 2 study in Anemia, AplasticNovartis · NCT04328727 · 36 enrolled · China, Japan, South Korea and more
- Apr 6, 2020Research Insight's first study: phase 4 study in Dry Eye SyndromesNew to Research InsightResearch Insight · NCT04342988 · 74 enrolled · United States
- Apr 8, 2020Phase 4 study in Dry Eye SyndromesSun Pharmaceutical Industries · NCT04357795 · 135 enrolled · United States
- Mar 19, 2024Phase 4 study in Dry Eye SyndromesNovaliq · NCT06329661 · 204 enrolled · United States
- Jun 25, 2024Phase 4 study in Dry Eye SyndromesResearch Insight · NCT06482177 · 52 enrolled · United States
- Jan 3, 2025zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd's first study: phase 3 study in Moderate to Severe Dry EyeNew to zhaoke-guangzhou-ophthalmology-pharmaceutical-ltdzhaoke-guangzhou-ophthalmology-pharmaceutical-ltd · NCT06766357 · 360 planned · China
- Jun 16, 2025Phase 4 study in Dry Eye SyndromesHoffmann-La Roche · NCT07025811 · 378 enrolled · United States
TargetBeta
“Cyclophilin A modulator”ChEMBL 37, by rule
Studies
The newest 60 of 81 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07025811Dry Eye Syndromes · United States | 4 | Completed | Hoffmann-La Roche | Jul 16, 2026 | 378 |
| NCT06766357Moderate to Severe Dry Eye · China | 3 | Recruiting | zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd | Feb 2026 | 360 |
| NCT06482177Dry Eye Syndromes · United States | 4 | Completed | Research Insight | Jun 5, 2024 | 52 |
| NCT06329661Dry Eye Syndromes · United States | 4 | Completed | Novaliq | Jul 30, 2025 | 204 |
| NCT04357795Dry Eye Syndromes · United States | 4 | Completed | Sun Pharmaceutical Industries | Jun 24, 2022 | 135 |
| NCT04342988Dry Eye Syndromes · United States | 4 | Completed | Research Insight | Dec 31, 2020 | 74 |
| NCT04328727Anemia, Aplastic · China, Japan, South Korea and more | 2 | Completed | Novartis | Jun 10, 2022 | 36 |
| NCT04144413Dry Eye Disease With Severe Keratitis · Czechia, France, Italy and more | 3 | Completed | Santen Pharmaceutical | Jul 14, 2023 | 350 |
| NCT04107675Bronchiolitis Obliterans Syndrome · France, Germany, Spain | 2 | Terminated | Zambon SpA | Jun 16, 2022 | 6 |
| NCT04039347Bronchiolitis Obliterans · United States, Austria, Belgium and more | 3 | Terminated | Zambon SpA | Feb 25, 2026 | 164 |
| NCT03844932Colitis, Ulcerative · United States, Belarus, Bulgaria and more | 2 | Terminated | sublimity-therapeutics-holdco-limited | Apr 14, 2021 | 235 |
| NCT03710044Dermatitis, Atopic · Netherlands | 4 | Withdrawn | LEO Pharma | Aug 2020 | 0 |
| NCT03657342Bronchiolitis Obliterans · United States, Belgium, France and more | 3 | Completed | Zambon SpA | Apr 16, 2024 | 62 |
| NCT03656926Bronchiolitis Obliterans · United States, Austria, Belgium and more | 3 | Completed | Zambon SpA | Mar 12, 2024 | 169 |
| NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more | 2 | Completed | Novartis | Nov 3, 2020 | 54 |
| NCT02865356Dermatitis, Atopic · Spain | 2 | Completed | spherium-biomed | Apr 12, 2017 | 36 |
| NCT02688556Keratoconjunctivitis Sicca · United States | 3 | Completed | Sun Pharmaceutical Industries | Nov 2016 | 745 |
| NCT02630563Pediatric Liver Transplantation · United States | 2 | Terminated | Hoffmann-La Roche | Jan 2005 | 9 |
| NCT02617667Dry Eye Syndromes · United States | 2 | Completed | Novaliq | Jul 2016 | 207 |
| NCT02554981Dry Eye Syndromes · United States | 4 | Completed | AbbVie | Mar 24, 2016 | 51 |
| NCT02404025Anemia, Aplastic · Japan | 2 | Completed | Novartis | Jul 5, 2016 | 10 |
| NCT02366585Periodontitis · Sweden | 2 | Completed | perioc-limited | Sep 2016 | 23 |
| NCT02229955Dry Eye Syndromes · Korea, Republic of | 3 | Completed | Hanlim Pharm. | Apr 2014 | 86 |
| NCT02130414Healthy | 1 | Completed | sigmoid-pharma | Jan 2015 | 48 |
| NCT02121847Dry Eye Syndromes · United States | 4 | Completed | AbbVie | Sep 23, 2014 | 40 |
| NCT02091414Heart Transplantation · China | 3 | Completed | Hoffmann-La Roche | Feb 2009 | 36 |
| NCT02005562Kidney Transplantation · France | 3 | Completed | Hoffmann-La Roche | Mar 2009 | 252 |
| NCT01843348Rejection, Psychology · France, Germany | 3 | Completed | Novartis | Mar 23, 2016 | 612 |
| NCT01762657Diabetes Mellitus, Type 1 | 3 | Withdrawn | perle-bioscience-inc | Sep 2015 | 0 |
| NCT01762644Diabetes Mellitus, Type 1 | 3 | Withdrawn | perle-bioscience-inc | May 2016 | 0 |
| NCT01751126Conjunctivitis, Allergic · United States, Croatia, France and more | 3 | Completed | Santen Pharmaceutical | Feb 2016 | 169 |
| NCT01768312Dry Eye Syndromes · Korea, Republic of | 3 | Completed | Hanlim Pharm. | Jul 31, 2013 | 84 |
| NCT01692834Healthy · South Africa | 1 | Completed | Pharming Group | Jan 2010 | 65 |
| NCT01601821Inflammation · Iran, Islamic Republic of | 4 | Completed | Pfizer | Mar 2008 | 245 |
| NCT01552629Dermatitis, Atopic · Austria, France, Germany | 2 | Completed | Novartis | Aug 28, 2013 | 22 |
| NCT01514968Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Feb 2012 | 18 |
| NCT01596062Renal Transplantation · France | 2 | Completed | Novartis | Mar 2013 | 16 |
| NCT01334892Bronchiolitis Obliterans · Germany | 3 | Terminated | pari-pharma-gmbh | Jul 2013 | 130 |
| NCT01276457Transplantation Infection | 3 | Completed | Novartis | Feb 2009 | 223 |
| NCT01120132Conjunctivitis, Allergic · United States | 2 | Completed | fovea-pharmaceuticals-sa | Aug 2010 | 716 |
| NCT01109498Hyperlipoproteinemia Type I · Canada | 3 | UNKNOWN | amsterdam-molecular-therapeutics | Jun 2013 | 14 |
| NCT01033305Mild to Moderate Ulcerative Colitis · Ireland, United Kingdom | 2 | Completed | sigmoid-pharma | Aug 2011 | 118 |
| NCT00991458Laser In Situ Keratomileusis · United States | 2 | Completed | AbbVie | Apr 2011 | 621 |
| NCT00938860Hepatitis C · United States, Belgium, Brazil and more | 4 | Completed | Novartis | May 2013 | 92 |
| NCT00938236Bronchiolitis Obliterans Syndrome · United States, Canada | 3 | Terminated | apt-pharmaceuticals-inc | Sep 2011 | 17 |
| NCT00891306Hyperlipoproteinemia Type I · Canada | 3 | Completed | amsterdam-molecular-therapeutics | Aug 2010 | 5 |
| NCT00884585Conjunctivitis, Allergic · United States, Australia, Canada and more | 3 | Completed | AbbVie | Oct 2010 | 176 |
| NCT00814515Lymphoma, Follicular · France | 3 | Completed | Santen Pharmaceutical | Sep 2009 | 482 |
| NCT00755781Bronchiolitis Obliterans Syndrome · United States, Canada | 3 | Completed | apt-pharmaceuticals-inc | Sep 2011 | 284 |
| NCT00739349Dry Eye Syndromes · United States | 2 | Completed | Santen Pharmaceutical | Jan 2009 | 132 |
| NCT00578370Psoriasis · Germany | 2 | Completed | isdin | Apr 2008 | 25 |
| NCT00549289Dry Eye Syndromes · United States | 3 | Completed | Sirion Therapeutics | ||
| NCT00548301Dry Eye Syndromes · United States | 3 | Completed | Sirion Therapeutics | ||
| NCT00518375Kidney Transplantation | 4 | Completed | Pfizer | 250 | |
| NCT00507793Kidney Transplantation | 4 | Completed | Pfizer | 385 | |
| NCT00504543Kidney Transplantation · Argentina, Australia, Austria and more | 2 | Completed | Novartis | Apr 2011 | 311 |
| NCT00502073Dry Eye Syndromes · United States | 3 | Completed | Sirion Therapeutics | ||
| NCT00438360Chronic Plaque Psoriasis · Italy | 3 | Completed | Novartis | Nov 2007 | 243 |
| NCT00428064Renal Transplantation | 3 | Completed | Pfizer | 408 | |
| NCT00419926Kidney Transplantation · Switzerland | 4 | Completed | Novartis | Jun 2009 | 313 |
How it is read
Names in the registry
- “cyclosporine”, 12 entries
- “Cyclosporine”, 10 entries
- “Cyclosporine A”, 6 entries
- “Ciclosporin”, 4 entries
- “Liposomal Cyclosporine A”, 3 entries
Codes read as this program: NOVA22007.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 15 studies
- Dermatitis, Atopic, 5 studies
- Bronchiolitis Obliterans Syndrome, 4 studies
- Conjunctivitis, Allergic, 4 studies
- Bronchiolitis Obliterans, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.